A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

The ACCESS-TAVI trial demonstrated that a combined suture/plug-based vascular closure device strategy significantly reduces ...

JenaValve announced today that it received the green light to begin a new randomized controlled trial for its Trilogy device.

Nov. 12, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV ... severe aortic regurgitation treated with the Trilogy device ...

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through ...

NeurAxis (NASDAQ:NRXS – Get Free Report) and Medtronic (NYSE:MDT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength ...

A new study published in the New England Journal of Medicine showed that improvements in symptoms and quality of life were ...

FDA approved the Varipulse pulsed field ablation (PFA) platform for drug refractory paroxysmal atrial fibrillation, Johnson & ...

3D transesophageal echocardiography is very useful for detailing the valve anatomy and assessing repairability and is essential for guiding transcatheter mitral and tricuspid valve procedures. CT ...